Reports Q2 revenue $14.3M, consensus $14.0M. “We are extremely pleased with Paysign’s second-quarter financial results, as we continue to grow our business at a rapid pace,” stated Mark Newcomer, President & CEO of Paysign. “In the second quarter, revenues grew 29.8%, and adjusted EBITDA grew 95.8%, driven by double-digit revenue growth in our plasma donor compensation business and an outstanding 266.8% revenue increase in our patient affordability business. Our gross margin percentage increased by 207 basis points, and we expect to see continued margin expansion as patient affordability remains a dominant growth driver for the company. Looking forward, we anticipate maintaining our current trajectory across our two major businesses of plasma donor compensation and pharma patient affordability while seeking additional high growth opportunities within the payments space. We remain committed to delivering sustainable growth and maximizing shareholder value.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAYS: